• +1-646-491-9876
    • +91-20-67278686

    Search

    Integrin Alpha 4-Pipeline Review H2 2017

    Integrin Alpha 4-Pipeline Review H2 2017

    • Report Code ID: RW0001881477
    • Category Life Sciences
    • No. of Pages 74
    • Publication Month Jul-17
    • Publisher Name Global Markets Direct
    Integrin Alpha 4 (CD49 Antigen Like Family Member D or VLA4 Subunit Alpha or CD49d or ITGA4)-Pipeline Review H2 2017

    Summary

    Integrin Alpha 4 (CD49 Antigen Like Family Member D or VLA4 Subunit Alpha or CD49d or ITGA4) pipeline Target constitutes close to 12 molecules. Out of which approximately 12 molecules are developed by Companies. The latest report Integrin Alpha 4-Pipeline Review H2 2017 outlays comprehensive information on the Integrin Alpha 4 (CD49 Antigen Like Family Member D or VLA4 Subunit Alpha or CD49d or ITGA4) targeted therapeutics complete with analysis by indications stage of development mechanism of action (MoA) route of administration (RoA) and molecule type.

    Integrin Alpha 4 (CD49 Antigen Like Family Member D or VLA4 Subunit Alpha or CD49d or ITGA4)-Integrin Alpha 4 is a protein encoded by ITGA4. Integrins alpha-4 (VLA-4) subunit associates with a beta 1 or beta-7 subunit to form an integrin that plays a role in cell motility and migration. This integrin is a therapeutic target for the treatment of multiple sclerosis Crohn's disease and inflammatory bowel disease. They are receptors for fibronectin. They recognize one or more domains within the alternatively spliced CS-1 and CS-5 regions of fibronectin. They are also receptors for VCAM1. The molecules developed by companies in Phase III Phase II Preclinical and Discovery stages are 2 4 3 and 3 respectively. Report covers products from therapy areas Gastrointestinal Immunology Infectious Disease Oncology Central Nervous System Respiratory Cardiovascular Genetic Disorders Ophthalmology and Toxicology which include indications Ulcerative Colitis Asthma Graft Versus Host Disease (GVHD) Human Immunodeficiency Virus (HIV) Infections (AIDS) Inflammatory Bowel Disease Acute Ischemic Stroke Acute Myelocytic Leukemia (AML Acute Myeloblastic Leukemia) Autoimmune Disorders Celiac Disease Chemotherapy Effects Crohn's Disease (Regional Enteritis) Duchenne Muscular Dystrophy Genital Warts (Condylomata Acuminata) Melanoma Multiple Sclerosis Paraneoplastic Syndrome Relapsing Remitting Multiple Sclerosis (RRMS) and Wet (Neovascular / Exudative) Macular Degeneration.

    Furthermore this report also reviews key players involved in Integrin Alpha 4 (CD49 Antigen Like Family Member D or VLA4 Subunit Alpha or CD49d or ITGA4) targeted therapeutics development with respective active and dormant or discontinued projects. Driven by data and information sourced from proprietary databases company/university websites clinical trial registries conferences SEC filings investor presentations and featured press releases from company/university sites and industry-specific third party sources.

    Note Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

    Scope

    - The report provides a snapshot of the global therapeutic landscape for Integrin Alpha 4 (CD49 Antigen Like Family Member D or VLA4 Subunit Alpha or CD49d or ITGA4)
    - The report reviews Integrin Alpha 4 (CD49 Antigen Like Family Member D or VLA4 Subunit Alpha or CD49d or ITGA4) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
    - The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
    - The report features descriptive drug profiles for the pipeline products which includes product description descriptive MoA R&D brief licensing and collaboration details & other developmental activities
    - The report reviews key players involved in Integrin Alpha 4 (CD49 Antigen Like Family Member D or VLA4 Subunit Alpha or CD49d or ITGA4) targeted therapeutics and enlists all their major and minor projects
    - The report assesses Integrin Alpha 4 (CD49 Antigen Like Family Member D or VLA4 Subunit Alpha or CD49d or ITGA4) targeted therapeutics based on mechanism of action (MoA) route of administration (RoA) and molecule type
    - The report summarizes all the dormant and discontinued pipeline projects
    - The report reviews latest news and deals related to Integrin Alpha 4 (CD49 Antigen Like Family Member D or VLA4 Subunit Alpha or CD49d or ITGA4) targeted therapeutics

    Reasons to buy

    - Gain strategically significant competitor information analysis and insights to formulate effective R&D strategies
    - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
    - Identify and understand the targeted therapy areas and indications for Integrin Alpha 4 (CD49 Antigen Like Family Member D or VLA4 Subunit Alpha or CD49d or ITGA4)
    - Identify the use of drugs for target identification and drug repurposing
    - Identify potential new clients or partners in the target demographic
    - Develop strategic initiatives by understanding the focus areas of leading companies
    - Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
    - Devise corrective measures for pipeline projects by understanding Integrin Alpha 4 (CD49 Antigen Like Family Member D or VLA4 Subunit Alpha or CD49d or ITGA4) development landscape
    - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
    Table of Contents
    List of Tables
    List of Figures
    Introduction
    Publisher Report Coverage
    Integrin Alpha 4 (CD49 Antigen Like Family Member D or VLA4 Subunit Alpha or CD49d or ITGA4)-Overview
    Integrin Alpha 4 (CD49 Antigen Like Family Member D or VLA4 Subunit Alpha or CD49d or ITGA4)-Therapeutics Development
    Products under Development by Stage of Development
    Products under Development by Therapy Area
    Products under Development by Indication
    Products under Development by Companies
    Integrin Alpha 4 (CD49 Antigen Like Family Member D or VLA4 Subunit Alpha or CD49d or ITGA4)-Therapeutics Assessment
    Assessment by Mechanism of Action
    Assessment by Route of Administration
    Assessment by Molecule Type
    Integrin Alpha 4 (CD49 Antigen Like Family Member D or VLA4 Subunit Alpha or CD49d or ITGA4)-Companies Involved in Therapeutics Development
    Antisense Therapeutics Ltd
    Biogen Inc
    BioMAS Ltd
    Daiichi Sankyo Company Ltd
    EA Pharma Co Ltd
    Immunwork Inc
    Morphic Therapeutic Inc
    Protagonist Therapeutics Inc
    Takeda Pharmaceutical Company Ltd
    Viriom Inc
    Integrin Alpha 4 (CD49 Antigen Like Family Member D or VLA4 Subunit Alpha or CD49d or ITGA4)-Drug Profiles
    AS-101-Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    ATL-1102-Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    carotegrast-Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    ET-3764-Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    natalizumab-Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    PTG-100-Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Small Molecule to Antagonize Integrin Alpha4 and Beta7 for Inflammatory Bowel Disease-Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Small Molecule to Antagonize VLA-4 for Asthma-Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Small Molecules to Antagonize Integrin Alpha 4 and Beta 2 for Autoimmune Disorders-Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    TE-5232-Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    vedolizumab-Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    VM-4500-Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Integrin Alpha 4 (CD49 Antigen Like Family Member D or VLA4 Subunit Alpha or CD49d or ITGA4)-Dormant Products
    Integrin Alpha 4 (CD49 Antigen Like Family Member D or VLA4 Subunit Alpha or CD49d or ITGA4)-Discontinued Products
    Integrin Alpha 4 (CD49 Antigen Like Family Member D or VLA4 Subunit Alpha or CD49d or ITGA4)-Product Development Milestones
    Featured News & Press Releases
    Jun 26 2017 Antisense Therapeutics to Enter Clinical Development in Duchenne Muscular Dystrophy
    Jun 26 2017 ATL1102 for Multiple Sclerosis-Phase IIb Investigational New Drug Application Submitted to the FDA
    May 09 2017 Provincial drug plans including Ontario and BC make ENTYVIO (vedolizumab) available to treat inflammatory bowel disease
    May 08 2017 New Real-World Analyses Support Effectiveness and Safety of Entyvio (vedolizumab) for Ulcerative Colitis and Crohns Disease
    Apr 24 2017 TYSABRI Data Demonstrates Improved Outcomes with Early MS Treatment at American Academy of Neurology in Boston
    Apr 24 2017 ATL1102 for Multiple Sclerosis-Phase IIb Investigational New Drug Submission
    Apr 18 2017 Biogen to Present Data on TYSABRI at AAN Congress
    Feb 17 2017 Five-Year Open-Label Prospective Study Data Presented at the 12th Congress of European Crohn;s and Colitis Organisation (ECCO) Provides Information on the Long-Term Use of Vedolizumab in Adult Patients with Moderate to Severely Active Ulcerative Colitis and Crohn's Disease
    Feb 17 2017 Protagonist Therapeutics Presents Data on Oral Peptide Drug Candidate PTG-100 at European Crohn's and Colitis Organization Congress
    Jan 17 2017 Protagonist Therapeutics Initiates Phase 2b Study of Oral Drug Candidate PTG-100 in Ulcerative Colitis
    Jan 05 2017 Key Patent is Issued Covering Protagonist Therapeutics' Alpha4Beta7 Integrin Peptide Inhibitors including Oral Drug Candidate PTG-100
    Dec 09 2016 GEMINI II & III Post-hoc Analysis Reports Clinical Benefits of Vedolizumab as Induction and Maintenance Therapy in Tumor Necrosis Factor-Naive Patients with Moderately to Severely Active Crohns Disease
    Dec 08 2016 Takeda Presents 17 Abstracts at the 2016 Advances in Inflammatory Bowel Diseases (AIBD) Annual Conference
    Nov 24 2016 Takeda's ENTYVIO (vedolizumab) receives positive reimburement recommendation from Common Drug Review for treatment of Crohns Disease
    Nov 23 2016 Takeda IBD Treatment ENTYVIO (vedolizumab) Receives Prestigious Prix Galien Canada Innovative Product Award
    Appendix
    Methodology
    Coverage
    Secondary Research
    Primary Research
    Expert Panel Validation
    Contact Us
    Disclaimer

    List of Tables

    Number of Products under Development by Stage of Development H2 2017
    Number of Products under Development by Therapy Areas H2 2017
    Number of Products under Development by Indication H2 2017
    Number of Products under Development by Companies H2 2017
    Products under Development by Companies H2 2017
    Products under Development by Companies H2 2017 (Contd..1) H2 2017
    Number of Products by Stage and Mechanism of Actions H2 2017
    Number of Products by Stage and Route of Administration H2 2017
    Number of Products by Stage and Molecule Type H2 2017
    Pipeline by Antisense Therapeutics Ltd H2 2017
    Pipeline by Biogen Inc H2 2017
    Pipeline by BioMAS Ltd H2 2017
    Pipeline by Daiichi Sankyo Company Ltd H2 2017
    Pipeline by EA Pharma Co Ltd H2 2017
    Pipeline by Immunwork Inc H2 2017
    Pipeline by Morphic Therapeutic Inc H2 2017
    Pipeline by Protagonist Therapeutics Inc H2 2017
    Pipeline by Takeda Pharmaceutical Company Ltd H2 2017
    Pipeline by Viriom Inc H2 2017
    Dormant Products H2 2017
    Dormant Products H2 2017 (Contd..1) H2 2017
    Dormant Products H2 2017 (Contd..2) H2 2017
    Discontinued Products H2 2017

    List of Figures

    Number of Products under Development by Stage of Development H2 2017
    Number of Products under Development by Therapy Areas H2 2017
    Number of Products under Development by Top 10 Indications H2 2017
    Number of Products by Mechanism of Actions H2 2017
    Number of Products by Stage and Mechanism of Actions H2 2017
    Number of Products by Routes of Administration H2 2017
    Number of Products by Stage and Routes of Administration H2 2017
    Number of Products by Molecule Types H2 2017
    Number of Products by Stage and Molecule Types H2 2017
    Antisense Therapeutics Ltd
    Biogen Inc
    BioMAS Ltd
    Daiichi Sankyo Company Ltd
    EA Pharma Co Ltd
    Immunwork Inc
    Morphic Therapeutic Inc
    Protagonist Therapeutics Inc
    Takeda Pharmaceutical Company Ltd
    Viriom Inc

    Request for Sample

    Report Url http://www.reportsweb.com//integrin-alpha-4-pipeline-review-h2-2017&type=sample
    Report Name
    First Name
    Last Name
    Email
    Phone
    Company
    Job Title
    Country
    Publisher
    Report Code
    Comments
     

    Inquire before Buying

    Report Url http://www.reportsweb.com//integrin-alpha-4-pipeline-review-h2-2017&type=buying
    Report Name
    First Name
    Last Name
    Email
    Phone
    Company
    Job Title
    Country
    Publisher
    Report Code
    Comments
     

    Inquire for Discount

    Report Url http://www.reportsweb.com//integrin-alpha-4-pipeline-review-h2-2017&type=discount
    Report Name
    First Name
    Last Name
    Email
    Phone
    Company
    Job Title
    Country
    Publisher
    Report Code
    Comments